ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADC Therapeutics SA (ADCT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators, the lack of strong proprietary trading signals, insider selling trends, and weak financial performance in the latest quarter suggest caution. The stock may be better suited for short-term trading rather than a long-term investment.
The technical indicators show a mixed picture. The MACD is positive and expanding, indicating bullish momentum. The RSI is at 85.299, which is in the overbought zone, suggesting a potential pullback. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its resistance level (R1: 4.574). However, the overbought RSI and proximity to resistance levels warrant caution.
Analyst Robert Burns raised the price target to $8 from $7 and maintained a Buy rating.
Revenue increased by 36.36% YoY in Q4
Gross margin improved to 92.63%, up 0.81% YoY.
Insiders are selling, with a significant increase of 1160.65% in the last month.
Net income dropped by -79.14% YoY, and EPS declined by -86.21% YoY in Q4
No recent news or event-driven catalysts to drive the stock higher.
In Q4 2025, revenue increased by 36.36% YoY to $23.06M, and gross margin improved slightly to 92.63%. However, net income dropped significantly to -$6.41M (-79.14% YoY), and EPS declined to -0.04 (-86.21% YoY), indicating weak profitability.
Analyst Robert Burns from H.C. Wainwright raised the price target to $8 from $7 and maintained a Buy rating. This reflects optimism but is not supported by strong financial or trading trends.
